Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia

Journal of Infection

Volumn 62, Issue 3, 2011, Pages 218-225

  Ewig, S ^a   Hecker, H ^b   Suttorp, N ^c   Marre, R ^d   Welte, T ^e  

^a Thoraxzentrum Ruhrgebiet   (Germany)

^b Charité Berlin ^*  (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Lactams; Community acquired pneumonia; Fluoroquinolones; Therapy

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; FEMALE; HEART DISEASE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NEOPLASM; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SEX DIFFERENCE; SMOKING; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; QUINOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952195049     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.01.009     Document Type: Article

References (18)

1. Kaplan V., Angus D.C., Griffin M.F., Clermont G., Scott Watson R., Linde-Zwirble W.T. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002, 165:766-772.
2. Ewig S., Birkner N., Strauss R., Schaefer E., Pauletzki J., Bischoff H., et al. New perspectives on community-acquired pneumonia in 388,406 patients. Thorax 2009, 64(12):1062-1069.
3. Rosón B., Carratalà J., Fernández-Sabé N., Tubau F., Manresa F., Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004, 164:502-508.
4. Aliberti S., Amir A., Peyrani P., Mirsaeidi M., Allen M., Moffett B.K., et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008, 134:955-962.
5. Welte T., Suttorp N., Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004, 32:234-238.
6. Johnstone J., Eurich D.T., Majumdar S.R., Jin Y., Marrie T.J. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008, 87:329-334.
7. Martínez J.A., Horcajada J.P., Almela M., Marco F., Soriano A., García E., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36:389-395.
8. García Vázquez E., Mensa J., Martínez J.A., Marcos M.A., Puig J., Ortega M., et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005, 24:190-195.
9. Tessmer A., Welte T., Martus P., Schnoor M., Marre R., Suttorp N. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother 2009, 63:1025-1033.
10. Baddour L.M., Yu V.L., Klugman K.P., Feldman C., Ortqvist A., Rello J., International Pneumococcal Study Group, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444.
11. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161:1837-1842.
12. Schwartz D.N. Potential mechanisms for mortality reduction associated with combination antibiotic therapy among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2005, 172:1472-1473.
13. Amsden G.W. Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 2005, 55:10-21.
14. Lodise T.P., Kwa A., Cosler L., Gupta R., Smith R.P. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrobial Agents Chemother 2007, 51:3977-3982.
15. Torres A., Garau J., Arvis P., Carlet J., Choudhri S., Kureishi A., MOTIV (MOxifloxacin Treatment IV) Study Group, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study - a randomized clinical trial. Clin Infect Dis 2008, 46:1499-1509.
16. Welte T., Petermann W., Schürmann D., Bauer T.T., Reimnitz P., MOXIRAPID Study Group Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005, 41:1697-1705.
17. Vardakas K.Z., Siempos I.I., Grammatikos A., Athanassa Z., Korbila I.P., Falagas M.E. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008, 179:1269-1277.
18. Finch R., Schürmann D., Collins O., Kubin R., McGivern J., Bobbaers H., et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrobial Agents Chemother 2002, 46:1746-1754.